Does a Mask Help With Pollen Allergy? Japan's Government Prints the Percentage

Why does the change of season set your nose off?

More than one thing is happening. Rhinitis splits into allergic and non-allergic forms, and inside the non-allergic group sits vasomotor rhinitis. The 2020 rhinitis practice parameter from the joint task force of the two US allergy societies describes patients whose main symptom is congestion this way: they appear to have nociceptive neurons with heightened sensitivity to stimuli such as temperature change, airborne irritants, foods (especially hot and spicy foods), alcoholic beverages, cold dry air, and exercise.

The example the same document gives makes the distinction concrete. The runny nose brought on by cold air and the one that follows a bowl of hot soup both responded to the same class of nasal medication, and the researchers read that as a reflex-mediated response. Korea's disease control agency describes the same condition in the same register, calling vasomotor rhinitis a chronic rhinitis arising from autonomic nervous system dysfunction, worsened by physical and environmental factors such as body temperature, humidity and poor air circulation, and by psychological ones such as stress, anxiety and fatigue.

That is where this article's axis comes from. A mask stops particles. It does not stop a nerve reflex. A nose reacting to pollen and a nose reacting to a change in temperature can produce the same week of symptoms and still call for different responses. Worth saying once and moving on: the phrase people search for, seasonal rhinitis, is everyday language rather than a diagnostic category in any country's classification.

Colds overlap too. The 2020 practice parameter notes that a pattern repeating with the seasons, an identifiable allergic trigger, and itching of the nose and eyes all point strongly toward allergic rhinitis, and that up to 98% of acute infectious rhinitis is viral. Its next point is the uncomfortable one. Viral rhinitis and sinusitis get mistaken for bacterial disease and treated with antibiotics, and recent studies put the antibiotic prescribing rate in acute infectious rhinitis at 69% to 79%. That is a guideline commenting on the prescribing habits of its own country.

Where the seasonal illness in question is influenza, the calendar itself becomes the subject, and the answers are national rather than universal: US guidance says finish by the end of October while Japan's says mid-December, because the two flu seasons peak at different times.

Does a mask actually do anything?

There is evidence. It does not extend to everyone. For two weeks beginning April 5, 2020, nurses at an Israeli medical center were surveyed, and 301 of them with allergic rhinitis were analyzed, 233 with intermittent and 68 with persistent disease. The intermittent group reported a significant improvement in overall symptom burden while wearing masks. The persistent group showed no change in symptom severity, with either a surgical mask or an N95. Eye symptoms did not change regardless of mask type.

Strip that caveat out and the sentence becomes dangerous. This was self-reported, in a single occupational group, which is also why the effect size does not belong in a headline number. Summarize it as "masks fix hay fever" and the person whose symptoms run all season is the one who stops looking for treatment. What the study supports is narrower and still useful: a mask reduces exposure, and for people whose symptoms persist, reducing exposure is not the whole answer.

How do three countries handle it?

Table: seasonal allergic rhinitis and pollen allergy response compared by country, covering where mask advice comes from, seasonal information infrastructure, and the drug class each clinical guideline puts first.

Two things need reading together here. The drug recommendations do not diverge; what diverges is who talks about masks and in what kind of document. And the phrase "no federal agency document was confirmed" in the US row means exactly that, not that no such document exists.

United States: the country that writes the recommendations

US

Most of the clinical spine of this article is an American document. The 2020 rhinitis practice parameter, produced by the joint task force of the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, puts an intranasal corticosteroid as the preferred agent when choosing monotherapy for persistent allergic rhinitis, at strong recommendation and high certainty. For initial treatment of moderate to severe seasonal allergic rhinitis in people 15 and older, it recommends an intranasal corticosteroid over a leukotriene receptor antagonist. And for people 12 and older with seasonal allergic rhinitis, it recommends against prescribing an oral antihistamine combined with an intranasal corticosteroid in preference to the corticosteroid alone as initial treatment. That last one runs directly into the common instinct that stacking medications is how you get better. A US society wrote down that stacking is not the initial answer.

Nasal antihistamines have their own place in the same document, recommended as an option for initial treatment of seasonal allergic rhinitis and as first-line monotherapy for non-allergic rhinitis, both strong with high certainty. For non-allergic rhinitis an intranasal corticosteroid also appears as an initial monotherapy option, at a weaker recommendation strength than in the allergic case. And nasal decongestants come with a limit attached: short-term, intermittent use only, because overusing a topical decongestant can produce a drug-induced rhinitis of its own.

American societies have not been silent on masks either. In patient-facing material from 2021, the president of the allergy college at the time said that masks people use for protection from COVID-19, particularly those filtering more particles like N95 or KN95 masks, also tend to filter out pollen. That was expert opinion in a society news item rather than a recommendation citing specific studies, and the same piece bundled it with starting allergy medication two to three weeks before symptoms are expected, seeing an allergist about immunotherapy, managing indoor humidity, keeping windows shut, wearing protective glasses outdoors and showering before bed.

Documents pointing the other way arrived in the same period. In North Carolina, Session Law 2024-16 took effect on June 27, 2024 when the legislature overrode the governor's veto. A health exemption added in May 2020 had permitted masks worn for the purpose of ensuring the physical health or safety of the wearer or others; the amendment narrowed that to a medical or surgical grade mask worn to prevent the spread of contagious disease, and set out that a person must temporarily remove a mask when a law enforcement officer requests it, or when a property owner or occupant requests it to verify identity. Wearing a mask for health reasons was not prohibited. What the law wrote down were the circumstances in which it comes off. In August 2024 Nassau County, New York enacted an ordinance criminalizing mask wearing for the purpose of concealing identity, with health and religious exceptions, and a disability rights organization filed a federal class action over it.

The natural conditions are moving in the meantime. An analysis of 821 site-years from 60 North American monitoring stations between 1990 and 2018 found the pollen season lengthened by 20 days and pollen concentrations increased 21%, with anthropogenic climate forcing explaining roughly 50% of the season-length trend and about 8% of the concentration trend. That is North American data and does not transfer to Korea or Japan, but for a reader in the United States it is the actual backdrop to the section above.

Japan: the ministry that publishes percentages

JP

The environment ministry's pollen allergy environmental health manual contains a section on preventing pollen exposure, and lists defenses in order: masks, glasses, clothing, hand washing and face washing, indoor ventilation and cleaning. The March 2022 revision reports experimental results this way. Compared with wearing no mask, an ordinary mask reduced pollen by roughly 70%, and a mask made for pollen allergy by roughly 84%. For glasses, ordinary ones cut it by about 40% and pollen-allergy glasses with a side shield by about 65%. Which edition you are reading matters, because the numbers changed between them. The January 2014 revision said a high-performance mask can block 95% or more, then added that choosing one that fits your face matters more, because pollen comes in through any gap at the side.

The same manual contradicts this article's title on its own. Medication alone, it says, makes it difficult to fully suppress pollen allergy symptoms, so self-care that protects you from the pollen exposure causing it and medical care using drugs need to happen at the same time. A government document declining to treat masks and medication as an either-or. The manual also introduces what it calls initial therapy, starting medication preventively before pollen dispersal begins or while symptoms are still very mild, to delay onset or keep symptoms lighter, and describes it as widely used. Neither the Korean nor the American material confirmed a concept institutionalized to that degree.

The scale behind all of this has been measured repeatedly. A national nasal allergy survey of otolaryngologists and their families was conducted in 1998, 2008 and 2019, and pollen allergy prevalence rose across those rounds from 19.6% to 29.8% to 42.5%. The sample is otolaryngologists and their families, which does not stand in for the general population. Tokyo has run its own prevalence survey for more than 30 years. The 2016 report, published in December 2017, put estimated cedar pollen allergy prevalence in the city at 48.8%, with earlier rounds at 10.0% in 1983 to 1987, 19.4% in 1996 and 28.2% in 2006. The report attached its own warning that criteria for determining prevalence and estimation methods changed between rounds, so the figures cannot simply be compared, and included 45.6% as a reference value recalculated on the older method.

The backbone of this section is what that Tokyo survey found people actually doing. Among respondents 15 and older (1,840, multiple answers allowed), the most common measure during pollen season was gargling, hand washing and face washing after coming home at 50.7%, followed immediately by blocking pollen with a mask or glasses when going out at 50.1%. Nearly a third, 29.9%, said they do nothing in particular. On medication (1,414 respondents), 35.5% used prescribed drugs from a medical institution, 28.1% over-the-counter products, and 32.2% used none. And 57.3% had not visited a medical institution for treatment. The top reason for not going was that the level was bearable without doing anything (45.3%). The second was that they were managing with self-care such as over-the-counter medicine or wearing a mask (44.1%). A metropolitan government survey recorded, in its own numbers, masks partly substituting for medical care.

Pollen allergy is also cabinet business here. A ministerial council on pollen allergy was established in the cabinet secretariat in April 2023, and an initial intensive response package was decided on October 11 of that year, aimed at accelerating the felling of cedar plantations. Residents want the same thing. In the Tokyo survey, the top request to the metropolitan government was research into a fundamental cure (43.3%), and the second was reducing airborne pollen by felling and pruning cedar forests (37.6%). A country where hay fever policy becomes forestry policy, with no counterpart in Korea or the United States.

The masks stayed, too. In a national internet cross-sectional survey conducted from September to November 2023 (28,481 respondents), 64.5% said they wear a mask routinely. The reasons listed included preventing respiratory infection at 70.3%, and alongside it, health reasons other than infection control such as allergy prevention at 21.4% and "because people around me are wearing one" at 12.9%. That 21.4% is a broad category including allergy prevention among other things, so it cannot be converted into a figure for pollen allergy.

South Korea: a national recommendation with a grade attached

KR

The chronic rhinitis entry on Korea's national health information portal, run by the disease control agency, contains this sentence about avoidance measures: before going out, consult the meteorological agency's pollen concentration risk index and, if needed, wear a KF94 mask. Most Korean readers know that as household common sense. It is on a national health agency page, with a filter grade specified.

The index it points to is a real service. The meteorological agency runs a pollen concentration risk index, predicting pollen concentration from temperature, wind speed, precipitation and humidity and converting it into a measure of allergy likelihood. It runs April through June for oak and pine and August through October for weeds, is issued twice a day at 6am and 6pm, and has four levels. Two service windows, spring and autumn, which is the whole reason the everyday Korean phrase for this season exists in the first place. The pollen season here is not one season but two.

The grade has its own local history. Health masks are licensed as quasi-drugs and must display a KF number on the outside. KF stands for Korea Filter, and KF80 filters at least 80% of particles averaging 0.6 micrometers, while KF94 and KF99 filter at least 94% and 99% of particles averaging 0.4 micrometers. Those numbers should not be read as pollen filtration rates. The licensing language was confirmed against yellow dust, particulate matter and infectious agents, and whether pollen appears in it is something this article could not verify. What is confirmed is the structure: a grading system built for particulate matter, pointed at pollen by a health agency. The same history shows up in surveys about why people wear masks. In Gallup Korea's Daily Opinion No. 536 (surveyed March 2023, 1,000 adults 18 and older), the share saying they would keep wearing a mask after the indoor mandate was lifted fell from 58% in March 2022 to 39%, and among those still wearing one, the reasons given were infection prevention at 58% and particulate matter at 34%. Particulate matter appearing as an answer option at all is the tell: masks were institutionalized here through air quality before infection.

On medication the country runs with the international consensus. The Korean allergy society's 2023 allergic rhinitis guideline on pharmacotherapy recommends antihistamines for mild intermittent disease and intranasal corticosteroids first for severe or persistent allergic rhinitis, and leaves the choice between an intranasal corticosteroid alone and a combination with an antihistamine to the patient as a conditional recommendation. The disease control agency page describes topical corticosteroids as first-line drugs, citing local action without systemic side effects. For scale, the rate of adults 19 and older reporting a physician diagnosis of allergic rhinitis was 21.2% in 2023, and has sat between 14% and 21% since 2010.

Why does the same mask sit in a different file in each country?

Three countries recommend the same drug classes. What differs is which institutional world the mask belongs to. In Japan it functions closer to an instrument of environmental policy: a ministry issues a manual, prints reduction percentages, and the resulting countermeasures run through forestry. In Korea it is a product of air quality regulation, where quasi-drug licensing and the KF grade existed first and a health agency later borrowed the grade for pollen. In the United States the same object also gets read as a question of identity and politics, because what the 2024 state law and county ordinance addressed was not filtration performance but the act of covering a face.

Time is layered into those differences. A 2014 academic paper on Japanese mask practice traces general adoption to the 1918 to 1919 influenza pandemic, the appearance of pollen-allergy masks in the 1970s, and their normalization in the 1980s, and reads the mask as a ritual that supplies a sense of control independent of its effect. That is cultural interpretation and should be read as such. On the other side sits the experience of a mask being read as a mark of contagion. In a study conducted during the first pandemic wave in 2020, Chinese Canadians and non-East-Asian Canadians were compared, and Chinese respondents almost uniformly saw mask wearers as people protecting themselves and others and felt safer around them, while non-East-Asian responses split. That is a Canadian sample from 2020 and does not transfer to the United States.

The period when mask use tracked political affiliation is worth one paragraph and no more. In Pew Research Center surveys, the share saying they usually wear a mask in stores was 92% among Democrats and Democratic leaners against 76% among Republicans and Republican leaners in the August 2020 round, and 93% against 83% in February 2021. By 2025 the gap had effectively closed, with 6% of Democrats and 2% of Republicans saying they had often worn a mask in the past month. Those are separate survey rounds, and in an article about rhinitis this is background rather than argument.

What can you actually try this season?

Everything below is drawn from what health authorities and medical societies actually wrote down. Ingredient names, doses and dosing schedules are outside this article. What to use and for how long is decided in a consultation.

First, know which step you are on. The European position paper on rhinosinusitis, EPOS 2020, drew the care pathway as four tiers: self-care, pharmacy, primary care, secondary and tertiary care. The self-care box in the acute stage contains two entries, consider saline spray or rinses, and avoid antibiotics. If symptoms run past 10 days or worsen after five, the pathway moves up to topical corticosteroids, decongestants for under 10 days, herbal medicines and saline, and antibiotics remain something to avoid even there. EPOS is a sinusitis document rather than an allergic rhinitis one, so it does not map across directly, but it is useful for locating which box you are in.

Second, some countries count the pharmacy as a step. The UK's national health service page states that allergic rhinitis can often be treated without seeing a GP, and directs people to a GP if treatment from a pharmacist is not working, noting that a GP can prescribe steroid nasal sprays or antihistamines. The order in which that page lists medications should not be read as an order of preference. What is confirmed is the route itself, pharmacy up to primary care.

Third, relearning how to use the spray is a formal step. In the chronic pathway of EPOS 2020, the primary care box prints "educate compliance/technique" alongside saline and topical corticosteroids, with reassessment after 6 to 12 weeks, and the self-care box includes self-education and e-Health material. This is the most useful line in the whole document, in our reading. A guideline conceded that a good share of "the spray isn't working" is about how the spray is being used, and then built the fix into the pathway.

Fourth, not everything you spray up your nose is the same thing. An intranasal corticosteroid and a nasal vasoconstrictor are different classes. The 2020 practice parameter recommends limiting nasal decongestants to short-term, intermittent use and notes that overusing a topical decongestant can cause a drug-induced rhinitis. The same document recommends nasal antihistamines as an option for initial treatment of seasonal allergic rhinitis and as first-line monotherapy for non-allergic rhinitis.

Fifth, saline rinsing sits in a different place in each document. The Korean allergy society's 2023 guideline on non-pharmacological management says saline nasal lavage can be selectively recommended for allergic rhinitis patients, a conditional recommendation at low quality of evidence, noting effects appearing within a month in both adults and children and minimal adverse events when appropriate sterile saline is used. EPOS 2020 puts it on the first line of self-care. The 2020 US practice parameter attaches it as an as-needed add-on across all four of its treatment algorithms rather than as a standalone first step. The UK health service goes as far as publishing how to make it. Very little money, low grade of evidence. Both are true at once.

Sixth, look at the seasonal information that exists. In Korea the meteorological agency's pollen concentration risk index runs April to June and August to October, twice a day, and it is the service the health agency's own recommendation points to. In the United States, pollen counts are run by private and society sources, and a national index was not something this article could confirm.

Seventh, fit beats grade. As the January 2014 revision of the Japanese ministry manual put it, even a high-performance mask lets pollen in through a gap at the side, and choosing one that fits your face matters more. That sentence is in a government manual.

Eighth, starting before the season is an established approach somewhere. The initial therapy described in the Japanese environment ministry manual means starting medication preventively before pollen dispersal begins, or while symptoms are still very mild, to delay onset or keep it lighter. American society patient material also advises starting medication two to three weeks before symptoms appear, though on the US side that is expert advice rather than a guideline recommendation.

Ninth, immunotherapy is less daunting if you know the procedure. The 2020 practice parameter says allergen immunotherapy can be considered when avoidance and medication are not controlling symptoms, when someone wants to avoid the side effects, cost or long duration of medication, or when prevention or reduction of a comorbidity such as asthma is the goal. The procedure is specific. Subcutaneous immunotherapy is given where measures to reduce the risk of anaphylaxis are in place and prompt recognition and treatment of anaphylaxis is assured, while sublingual immunotherapy has only its first dose given under supervision at a medical facility, after which the patient continues at home, with reassessment every 6 to 12 months. The Korean society guideline says the two routes are equally effective and the choice runs on patient values and preference, a conditional recommendation at moderate evidence, adding that adherence is better with the subcutaneous route but the risk of systemic adverse reactions is higher. Coverage, cost and access routes are outside what this article verified.

Tenth, there is a box after medication. The Korean society's non-pharmacological guideline selectively recommends inferior turbinate volume reduction surgery for patients whose symptoms do not improve on medication, particularly for congestion and runny nose, a conditional recommendation at very low quality of evidence, with symptom improvement reported beyond one year.

Do air purifiers and new bedding help?

This is the section that touches your money directly. The Korean allergy society's 2023 non-pharmacological guideline says air purifiers, impermeable bedding and cleaning can be selectively recommended to reduce indoor dust mite concentration, sets the quality of evidence at very low, and records alongside it that mite concentrations fell but symptom improvement was not significant. Pet-related measures have the same shape. Air purifiers, bathing and avoidance carry a selective recommendation, and even when allergen levels dropped, overall nasal symptoms did not improve significantly. That is not a verdict of no effect. The recommendation stands, the grade of evidence is very low, and the guideline itself wrote down the limit on symptom improvement.

On acupuncture, the 2020 US practice parameter states that it cannot make a recommendation for or against its use in treating allergic rhinitis, at very low certainty. Unable to recommend and shown not to work are different findings.

Antihistamines for a cold have been settled too. In a Cochrane review cited by EPOS 2020, there was a limited effect on overall symptom severity on days one and two of treatment in adults, nothing in the medium or long term, and no clinically significant effect on nasal obstruction, rhinorrhoea or sneezing.

One item needs separating out to avoid confusion. Unlike the saline rinsing for allergic rhinitis described above, a study adding saline to antibiotics in acute bacterial sinusitis found no difference between hypertonic spray, isotonic spray and no treatment, and EPOS 2020 stated the quality of evidence was too low to make a recommendation. The same saline reads differently depending on which condition the document is about.

When should you see a doctor?

Scope first. Of the sources below, EPOS 2020 from Europe and the 2012 IDSA guideline from the United States are sinusitis guidelines, not allergic rhinitis guidelines. So this splits in two: signs that a seasonal nose has moved toward sinusitis, and signs that rhinitis itself should stop being self-managed. This is not a self-diagnosis checklist, and it is not for assigning yourself a condition.

The first layer is dates. EPOS 2020 defines acute viral rhinosinusitis, the common cold, as symptoms lasting under 10 days. If symptoms worsen after five days or persist past 10, the classification changes. The same guideline is explicit that the post-viral stage should not be diagnosed before 10 days unless there is clear worsening after five. The point of this layer is that it hands you dates rather than telling you to judge by mucus colour. On the allergic side, the discriminating axis is repetition. EPOS 2020 describes allergic rhinitis as producing similar symptoms in response to similar exposures, often with a seasonal pattern, with non-purulent discharge, itching and sneezing, reversible spontaneously or with treatment.

Thresholds for suspecting bacterial disease differ by guideline. The 2012 IDSA guideline from the United States lists three: symptoms lasting 10 days or more without evidence of clinical improvement; high fever of 39C or above with purulent nasal discharge or facial pain for at least three to four consecutive days early in the illness; and new onset of fever, headache or increased nasal discharge after a typical viral upper respiratory infection that had been improving. EPOS 2020 from Europe requires at least three of five, namely discoloured mucus, severe local pain, fever above 38C, raised inflammatory blood markers and double sickening, and notes that many cases of acute bacterial rhinosinusitis are unilateral. The fever thresholds are 39C in the 2012 American guideline and 38C in the European one. Deciding which is right is not this article's job, and blood markers are not something to check at home. Read that item only as a reminder that what clinicians look at includes blood tests.

The second layer is one side only. The differential table in the 2020 practice parameter states in its own footnote that it was developed largely on expert opinion and is intended to offer considerations for the clinician. In that table, progressive unilateral congestion with bloody discharge and nasal or ear pain puts nasal tumours on the differential list. Unilateral clear discharge that is intermittent, increases with a dependent head position and follows recent surgery or trauma raises cerebrospinal fluid leak, which typically appears without congestion, worsens sitting or standing, and can also occur spontaneously. In children, unilateral bad odour with mucopurulent discharge suggests a foreign body. Septal abnormalities are worse on one side. Once things pass 12 weeks into the chronic range, the immediate-referral list in EPOS 2020 adds unilateral symptoms, bleeding, crusting and cacosmia. None of this means a blocked nostril is a tumour. What the documents support is narrower: one side only, progressing, with blood in it, is outside the range of self-management.

The third layer is eyes, forehead and consciousness. EPOS 2020 tabulates warning symptoms of complications in acute rhinosinusitis that require immediate referral or hospitalization: periorbital oedema or erythema, displaced globe, double vision, ophthalmoplegia, reduced visual acuity, severe unilateral or bilateral frontal headache, frontal swelling, signs of meningitis, neurological signs and reduced consciousness. The integrated care pathway diagrams add signs of sepsis to that list. This is a list of sinusitis complications, not a list of allergic rhinitis symptoms, and it applies when a seasonal nose has moved in that direction. The same guideline states that these complications are uncommon but vital to identify early, that they occur early in the course of the illness, and that primary care clinicians need to be vigilant for them, and reports that in observational studies the outcome of these complications was not determined by whether antibiotics were used. Meaning this is not the layer where you count more days.

The chest belongs in this section too. EPOS 2020 states that a significant number of rhinosinusitis patients have lower respiratory tract involvement, and that a patient's own assessment of chest symptoms and severity is often poor, to the point that they may be unaware the lower airway is affected at all, so objective assessment is necessary. The four it names are wheeze, shortness of breath, chest tightness and cough. The UK health service lists, among reasons to see a GP, that you also have asthma and it is getting worse. The Korean society's non-pharmacological guideline selectively recommends allergen immunotherapy to prevent asthma in patients with allergic rhinitis, a conditional recommendation at high quality of evidence.

Unalarming signs also count as reasons to book. The UK health service lists five reasons to see a GP with allergic rhinitis: your symptoms get worse; you also have asthma and it is getting worse; your symptoms are affecting your sleep and everyday life; you are not sure what is causing your symptoms; treatments from a pharmacist are not working. Half that list is about daily life rather than emergencies. If your habit is to put up with it every season, the third and fifth are probably about you.

If you are pregnant, there is one more line. The 2020 practice parameter recommends that oral decongestants be avoided during the first trimester, a strong recommendation at low certainty. Pregnancy itself can produce congestion: increased estrogen dilates nasal vessels and progesterone and estrogen increase eosinophil migration in the nasal mucosa, and the same document states that pregnancy-associated rhinitis presents as congestion but its exact mechanism is unknown. This article does not suggest a substitute medication. That is a conversation with the clinician managing the pregnancy.

For children, different items attach. The differential table in the 2020 practice parameter lists adenoid hypertrophy where recurrent otitis media and snoring appear and congestion is the main or only symptom, with possible sleep disturbance, and unilateral bad odour with mucopurulent discharge points to a foreign body as noted above. EPOS 2020 states that chronic sinusitis in children can signal a serious underlying condition such as immunodeficiency, cystic fibrosis or primary ciliary dyskinesia. Age-banded day counts and temperature thresholds for children were not verified against primary sources for this article and are therefore not given.

Frequently asked questions

Frequently asked

My allergy season feels longer than it used to. Is that real?

For North America there is data. An analysis of 60 monitoring stations from 1990 to 2018, covering 821 site-years, found the pollen season lengthened by 20 days and pollen concentrations rose 21%, with anthropogenic climate forcing explaining roughly half the season-length trend and about 8% of the concentration trend. That finding is specific to North America and this article does not extend it to other regions.

Will an N95 filter pollen?

In 2021 society patient material, the allergy college's president at the time said masks that filter more particles, like N95 or KN95 masks, also tend to filter out pollen. That was expert opinion rather than a recommendation citing studies. What a study does show has limits: among nurses with allergic rhinitis, the intermittent group improved while the persistent group saw no change in severity with either a surgical mask or an N95, and eye symptoms did not change with any mask type. And as the Japanese ministry manual puts it, a mask that fits your face matters more than its rating, because pollen enters through gaps at the side.

Should I add an antihistamine to my steroid nasal spray?

Not as the initial move, according to the 2020 US practice parameter, which recommends against prescribing an oral antihistamine combined with an intranasal corticosteroid in preference to the corticosteroid alone for initial treatment of seasonal allergic rhinitis in people 12 and older. The Korean society's guideline treats the choice between corticosteroid alone and a combination as something the patient can decide, a conditional recommendation at low evidence. Which class, and for how long, is decided with the clinician prescribing it.

Can I be asked to take off a mask in public in the United States?

In some places, in certain circumstances, yes. North Carolina's Session Law 2024-16, effective June 2024, narrowed the health exemption to a medical or surgical grade mask worn to prevent the spread of contagious disease, and set out that a person temporarily remove it when a law enforcement officer requests it or when a property owner or occupant requests it to verify identity. Wearing a mask for health reasons remains permitted. Nassau County, New York enacted a separate ordinance in August 2024 criminalizing mask wearing to conceal identity, with health and religious exceptions, and a disability rights organization filed a federal class action. This article does not have the outcome of that litigation.

Are air purifiers and mattress covers worth the money?

The Korean allergy society's 2023 non-pharmacological guideline keeps a selective recommendation for air purifiers, impermeable bedding and cleaning as ways to reduce indoor dust mite concentration, at very low quality of evidence, and records that mite concentrations fell while symptom improvement was not significant. The recommendation stands. The guideline wrote down its own limit, which is the honest version of the answer.